187 related articles for article (PubMed ID: 34637151)
1. Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Wang EQ; Le V; Winton JA; Tripathy S; Raje S; Wang L; Dowty ME; Malhotra BK
J Clin Pharmacol; 2022 Apr; 62(4):505-519. PubMed ID: 34637151
[TBL] [Abstract][Full Text] [Related]
2. Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Wang EQ; Le V; O'Gorman M; Tripathy S; Dowty ME; Wang L; Malhotra BK
J Clin Pharmacol; 2021 Oct; 61(10):1311-1323. PubMed ID: 33749838
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Wang X; Dowty ME; Wouters A; Tatulych S; Connell CA; Le VH; Tripathy S; O'Gorman MT; Winton JA; Yin N; Valdez H; Malhotra BK
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):419-429. PubMed ID: 35226304
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
6. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Bauman JN; Doran AC; King-Ahmad A; Sharma R; Walker GS; Lin J; Lin TH; Telliez JB; Tripathy S; Goosen TC; Banfield C; Malhotra BK; Dowty ME
Drug Metab Dispos; 2022 Aug; 50(8):1106-1118. PubMed ID: 35701182
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Xin Y; Kawashima J; Weng W; Kwan E; Tarnowski T; Silverman JA
J Clin Pharmacol; 2018 Apr; 58(4):522-532. PubMed ID: 29283448
[TBL] [Abstract][Full Text] [Related]
9. Abrocitinib: First Approval.
Deeks ED; Duggan S
Drugs; 2021 Dec; 81(18):2149-2157. PubMed ID: 34807428
[TBL] [Abstract][Full Text] [Related]
10. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.
Wojciechowski J; Malhotra BK; Wang X; Fostvedt L; Valdez H; Nicholas T
Clin Pharmacokinet; 2022 May; 61(5):709-723. PubMed ID: 35061234
[TBL] [Abstract][Full Text] [Related]
12. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
[TBL] [Abstract][Full Text] [Related]
14. Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes.
Silverberg JI; Thyssen JP; Simpson EL; Yosipovitch G; Ständer S; Valdez H; Rojo R; Biswas P; Myers DE; Feeney C; DiBonaventura M
Am J Clin Dermatol; 2021 Jul; 22(4):541-554. PubMed ID: 33954933
[TBL] [Abstract][Full Text] [Related]
15. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
Nezamololama N; Crowley EL; Gooderham MJ; Papp K
Expert Opin Investig Drugs; 2020 Sep; 29(9):911-917. PubMed ID: 32741227
[TBL] [Abstract][Full Text] [Related]
16. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Mohamed MF; Trueman S; Feng T; Anderson J; Marbury TC; Othman AA
J Clin Pharmacol; 2019 Jun; 59(6):856-862. PubMed ID: 30633369
[TBL] [Abstract][Full Text] [Related]
18. Abrocitinib in atopic dermatitis: review of the current literature and clinical trials.
Napolitano M; Fornaro L; Potestio L; Fabbrocini G; Patruno C
Drugs Today (Barc); 2022 Aug; 58(8):373-387. PubMed ID: 35983924
[TBL] [Abstract][Full Text] [Related]
19. Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil.
Cho YS; Noh YH; Lim HS; Cho SH; Ghim JL; Choe S; Kim SB; Park JS; Lee SK; Yang WS; Chang JW; Bahng MY; Bae KS
J Clin Pharmacol; 2018 Jul; 58(7):905-912. PubMed ID: 29537612
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
Meher BR; Mohanty RR; Padhy BM
J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
